Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma(MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT07814170
What this trial is testing

A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece

Who this might be right for
Blood CancersLeukemiaLymphoma+13 more
University of West Attica 80
Testing effectiveness (Phase 2)UnknownNCT00800059
What this trial is testing

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
Ottawa Hospital Research Institute 27
Testing effectiveness (Phase 2)Study completedNCT00965224
What this trial is testing

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Who this might be right for
Acute Myeloid LeukemiaChronic Myeloid LeukemiaMultiple Myeloma
Zwi Berneman 38
Very early researchLooking for participantsNCT05846880
What this trial is testing

VitD3 Supplementation in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amany Keruakous, MD, MS. 100
Not applicableEnded earlyNCT00038818
What this trial is testing

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Who this might be right for
Chronic Myelogenous LeukemiaMultiple MyelomaNon Hodgkin's Lymphoma+2 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Looking for participantsNCT07638683
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Who this might be right for
Multiple MyelomaAL Amyloidosis
Shanghai Zhongshan Hospital 30
Post-approval studies (Phase 4)Looking for participantsNCT06057402
What this trial is testing

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Pfizer 80
Post-approval studies (Phase 4)Active Not RecruitingNCT03829371
What this trial is testing

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Who this might be right for
Multiple Myeloma
University of Turin, Italy 450
Testing effectiveness (Phase 2)Study completedNCT00065351
What this trial is testing

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 222
Testing effectiveness (Phase 2)Study completedNCT02636010
What this trial is testing

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 20
Early research (Phase 1)Study completedNCT01440582
What this trial is testing

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 77
Not applicableNo Longer AvailableNCT02568943
What this trial is testing

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Early research (Phase 1)Study completedNCT04634435
What this trial is testing

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Biohaven Pharmaceuticals, Inc. 7
Testing effectiveness (Phase 2)Ended earlyNCT02587598
What this trial is testing

Study of INCB053914 in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumors
Incyte Corporation 97
Early research (Phase 1)Looking for participantsNCT06271252
What this trial is testing

Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Who this might be right for
Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasms+11 more
OriCell Therapeutics Co., Ltd. 81
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more
Sumitomo Pharma America, Inc. 606
Testing effectiveness (Phase 2)Looking for participantsNCT06115135
What this trial is testing

Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics 39
Not applicableStudy completedNCT05428163
What this trial is testing

Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients

Who this might be right for
Multiple Myeloma
Assistance Publique Hopitaux De Marseille 20
Testing effectiveness (Phase 2)Looking for participantsNCT06759181
What this trial is testing

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Xuzhou Medical University 20
Next Page